David Bowen

Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes

Multi-national survey of transfusion experiences and preferences of patients with myelodysplastic syndrome.

Intubation Practices and Adverse Peri-intubation Events in Critically Ill Patients From 29 Countries

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

<i>SF3B1</i>-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

Time-dependent changes in mortality and transformation risk in MDS

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)

Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee

Validation of the revised international prognostic scoring system (<scp>IPSS</scp>‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet <scp>MDS</scp> (<scp>EUMDS</scp>) registry

Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

Outcomes in <scp>RBC</scp> transfusion‐dependent patients with <scp>L</scp>ow‐/<scp>I</scp>ntermediate‐1‐risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the <scp>MDS</scp>‐004 study

Clinical and biological implications of driver mutations in myelodysplastic syndromes

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes

Building Engineering Team Skills